rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Amneal Pharmaceuticals, Inc.

AMRX · Nasdaq

Health CarePharmaceuticalsLeading

AMRX stood above a rising 150-day average in 50 of the last 52 weekly readings, including each of the last 22 weeks. It is 27.2% above that average now. Pharmaceuticals: 35% of its 74 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
22 in a row
Industry in uptrend
35% -4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$17.5M
Officials’ trades on record
2
Institutions holding
283 (-6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 50 of 52 weeks.

23 Apr – 22 Oct
27%37%47%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$44.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 2, Senate 0, executive 0; 2 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39sold$1k–$15k29 May 2019filed 18 Jun 2019
Josh Gottheimer House: U.S. House ClerkNJ05sold$1k–$15k24 May 2019filed 15 Jun 2019

Insiders

Buy orders, 12 months0
Sale orders, 12 months7
Buyers · sellers0 · 5
WhoDidSharesTraded
John KielyDirectorsold50,000at $17.6413 Aug 2026filed 14 Aug 2026
Jason B. DalyEVP, Chief Legal Officersold210,000at $17.4012 Aug 2026filed 13 Aug 2026
Nikita ShahExecutive Vice Presidentsold146,403at $17.5112 Aug 2026filed 13 Aug 2026
Jason B. DalyEVP, Chief Legal Officersold6,613at $17.7011 Aug 2026filed 13 Aug 2026
Deborah M. AutorDirectorsold34,819at $12.9411 May 2026filed 12 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders283-6 on the quarter
New · exited47 · 52
Reported value$2.8B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202626,562,093$459.8M+2,042,901+8.3%
TPG GP A, LLCunchanged · filed 14 Aug 202612,328,767$213.4M00.0%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 202612,137,727$210.1M+812,794+7.2%
Rubric Capital Management LPreduced · filed 14 Aug 202610,168,660$176.0M-868,929−7.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,710,126$133.5M+125,092+1.6%
STATE STREET CORPadded · filed 7 Aug 20267,356,977$127.3M+562,275+8.3%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20265,794,263$100.3M+103,677+1.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20265,139,449$89.0M+593,401+13.1%
MORGAN STANLEYreduced · filed 13 Aug 20264,110,028$71.1M-527,157−11.4%
NEUBERGER BERMAN GROUP LLCadded · filed 13 Aug 20263,887,179$67.3M+204,895+5.6%
31 Mar 2023 – 30 Jun 2026
113198282Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

J. Kevin Buchi Company insiderDirector · last 17 Sep 20260 · 0
Andrew S. Boyer Company insiderExecutive Vice President · last 1 Sep 20262 · 6
John Kiely Company insiderDirector · last 13 Aug 20261 · 4
Jason B. Daly Company insiderEVP, Chief Legal Officer · last 12 Aug 20260 · 7
Nikita Shah Company insiderExecutive Vice President · last 12 Aug 20260 · 11
Chintu Patel Company insiderCo-CEO · last 10 Aug 20266 · 0
Chirag K. Patel Company insiderPresident & Co-CEO · last 10 Aug 20266 · 0
Gautam Patel Company insiderDirector · last 10 Aug 20263 · 9
Tushar Bhikhubhai Patel Company insider10% owner · last 10 Aug 20260 · 1
Deborah M. Autor Company insiderDirector · last 11 May 20260 · 5
Jeffrey P. George Company insiderDirector · last 7 May 20261 · 0
Paul M. Meister Company insiderDirector · last 7 May 20262 · 0

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202536.9%
Operating profit marginFY 2025 · to 31 Dec 202513.1%
Free cash flow marginFY 2025 · to 31 Dec 20258.9%
Return on capital employedFY 2025 · to 31 Dec 202514.1%
Cash conversionFY 2025 · to 31 Dec 2025472%
Research spendFY 2025 · to 31 Dec 20256.2%
Share count trendFY 2025 · to 13 Feb 2026-3.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$282.0M
Free cash flowFY 2025 · to 31 Dec 2025$269.9M

Analyst forecasts

No analyst forecasts yet.